Eisai Company, Limited

Eisai R&d Management Co., Ltd.

Tetsuya Hirakawa

Shigeki Hibi

Yoshinori Takahashi

Hisashi Shibata

Motohiro Soejima

Yorihisa Hoshino

Kogyoku Shin

Tatsuya Yoshiuchi

Mitsuhiro Ino

Koichi Kikuchi

Mutsuko Ono

Kouichi Kikuchi

Mutsuko Tabata

Takayuki Hida

The present invention provides a novel compound having an excellent corticotrophin-releasing-factor receptor antagonistic activity. That is, it provides a compound represented by the following formula or a salt thereof. Wherein Rdenotes a hydrogen atom, a Calkyl group, a Calkoxy group and the like; Rdenotes a halogen atom, a cyano group, a nitro group, a Calkyl group, a Calkenyl group, Calkynyl group and the like; Rdenotes a Caromatic hydrocarbon cyclic group or a 5- to 14-membered aromatic heterocyclic group, each of which may have a substituent; and X, Y and X are independent of each other and each denotes N or CR(wherein Rdenotes a hydrogen atom, a halogen atom, a cyano group, a nitro group, an optionally halogenated Calkyl group and the like) and, in this case, at least two of X, Y and Z denote CR.

Imidazo[1,2-b]pyridazine compound

Compounds represented by the general formula: [wherein Rrepresents methoxy, ethyl, methylthio, etc., R, Rand Reach represent hydrogen, a halogen, etc., Rand Reach represent &#x2014;X&#x2014;X&#x2014;X(wherein Xrepresents a single bond or &#x2014;CO&#x2014;, Xrepresents a single bond, &#x2014;NR, etc. and Xand Reach represent hydrogen, Calkyl, etc.), and Ar represents phenyl, pyridyl, etc.], salts thereof and hydrates of the foregoing.

Pyrazolo[1,5-a]pyridines and medicines containing the same

Pyrazolo[1,5-a] pyridines and medicines containing the same

The present invention provides a novel compound having an excellent corticotrophin-releasing-factor receptor antagonistic activity. That is, it provides a compound represented by the following formula, a pharmacologically acceptable salt thereof or hydrates thereof,wherein Ris a hydrogen atom, etc.; Ris a hydrogen atom, etc.; M' represents a hydrogen atom, a halogen atom or a Calkyl group; R&#x2032; represents a hydrogen atom or a Calkyl group; and W&#x2032; represents a phenyl group, pyridyl group, thienyl group, or furyl group, each being optionally substituted; and a pharmacologically acceptable salt thereof or hydrates thereof.

Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it

The present invention provides a novel compound having an excellent corticotrophin-releasing-factor receptor antagonistic activity. That is, it provides a compound represented by the following formula, a pharmacologically acceptable salt thereof or hydrates thereof.Wherein A, B and D are the same as or different from each other and each represents a group represented by the formula &#x2014;(CRR)&#x2014; (wherein Rand Rare the same as or different from each other and each represents a Calkyl group etc.), &#x2014;NR&#x2014; (wherein Rrepresetns hydrogen etc.) etc.; E and G are the same as or different from each other and each represents a group represented by the formula &#x2014;(CRR)&#x2014; (wherein Rand Rare the same as or different from each other and each represents hydrogen etc.; and p represents an integer of 0, 1 or 2); J represents a carbon atom or nitrogen atom, each substituted with Calkyl group optionally substituted with a halogen atom, etc.; K and L are the same as or different from each other and each represents carbon atom or nitrogen atom; M means hydrogen, a halogen atom, an optionally substituted Calkyl group etc.; and the partial structuremeans a single or double bond.

Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same

The present invention provides a novel compound having an excellent corticotrophin-releasing-factor receptor antagonistic activity. That is, it provides a compound represented by the following formula, a pharmacologically acceptable salt thereof or hydrates thereof,wherein

Growing community of inventors

Tsukuba, Japan

Tetsuya Hirakawa